LB Pharmaceuticals Inc Derivative Liability, Noncurrent
LB Pharmaceuticals Inc (LBRX) had Derivative Liability, Noncurrent of $1.41 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-11
- 2026-06-30: Derivative Liability, Noncurrent $1.41M.
- 2026-03-31: Derivative Liability, Noncurrent $1.14M.
- 2025-12-31: Derivative Liability, Noncurrent $1.34M.
- 2025-09-30: Derivative Liability, Noncurrent $942.00K.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.14M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.34M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $942.00K 10-Q · filed 2025-11-06 |
| 2024-12-31 | $2.50M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |